9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Estimated reading time: < 1 min

Condition: Solid Tumor

Estimated Enrollment: 121

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Safety, tolerability and maximum tolerated dose of orally administered PXD101 for each cohort,  Determine the pharmacokinetics of oral PXD101 when dosed once or twice daily at various dose levels,  Explore anti-tumor activity, Determine the safety, tolerability, and anti-tumor activity of orally administered PXD101 to patients with lymphoma

Interventions: oral belinostat,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: August 2011

Completion Date: August 2011

Last  Posted Date: July 8, 2015

Location: Yale New Haven Hospital, New Haven, Connecticut, United States

Website Link: https://ClinicalTrials.gov/show/NCT00413075

Was this article helpful?
Dislike 0